Sanofi and Regeneron hosted a conference call for the financial community focusing on investigational dupilumab following the late breaking data presentation from two trials evaluating dupilumab for inadequately controlled moderate-to-severe atopic dermatitis (SOLO 1 and SOLO 2) at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria.
Related press releases
- October 1, 2016: Press Release - Sanofi and Regeneron Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in The New England Journal of Medicine
- September 26, 2016: Press Release - Sanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA